Purpose/Objective: To derive a reference, based on portal imaging acquisitions, to ensure the constance and stability of FFF beams using the parameters defined in Med. Phys. (39), 2012. Materials and Methods: On Varian TrueBeam linac, the PV-aS1000 detector response was investigated for 6 and 10 MV FFF beams. With an adequate source to detector distance, e.g. SDD=150 cm, even with the maximum dose rate of 1400 and 2400 MU/min the integrated image does not present saturation. This allows its usage for dosimetric evaluations also for FFF beams. Feasibility tests were performed on four different TrueBeam machines (two equipped with a highdefinition MLC, HD-120MLC, and two with a standard Millenium 120-MLC) for a predefined set of beam settings. Comparisons with calculations in the Eclipse treatment planning system with AAA (Anisotropic Analytical Algorithm) were also carried out. Different open square and rectangular fields were periodically acquired for 6 and 10 MV FFF beams at SDD=150 cm for the maximum available dose rate, as well as at SDD=100 cm using a lower dose rate (800 MU/min), over a period of six months. Integrated images were converted into absorbed dose to water through the GLAaS algorithm [Med Phys (33), 2006], adapted to FFF beams. Data were analysed and different parameters were recorded: dose on the beam central axis, profile parameters as unflatness,slope, peak position and symmetry. Similar analysis was also derived from measurements acquired with 2-D ion chamber array, StarCheck (PTW), and used as benchmark. Results: Dose profile percentage differences within the 80% of the field size, between measurements and AAA calculations, resulted in -0.5±0.8% and -0.8±0.7% for 6 and 10 MV FFF, respectively. Similar deviation values were recorded for unflatness, symmetry and peak position. Constancy of repeated periodic portal image acquisition converted into dose resulted in the following values: output factors variation -0.13±0.17%, dose difference in the field region (80% of the field size): 0.15±0.26%. The gamma evaluation was conducted with two sets of distance-to-agreement and dose difference criteria of 2mm/2% and 1mm/2%. The corresponding percentage of point passing the gamma evaluation were 99.7±0.6% and 99.3±1.6%, respectively for the two criteria. Conclusions: The possibility to effectively use the Portal Vision for open field quality assurance of FFF beams was assured. Constancy and stability evaluated with the profile parameters were consistent with other measurements or calculations. This fact allows to set-up fast and safe linac quality assurance procedures also for FFF beams.
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Pre-treatment IMRT quality assurance: sensibility and specificity analysis of gamma index method. S. Bresciani 1 , A. Maggio 1 , A. Miranti 1 , A. Di Dia 1 , C. Cutaia 1 , E. Infusino 1 , M. Stasi 1 1 Institute of Cancer Research and Treatment, Medical Physics, Candiolo (Turin) , Italy Purpose/Objective: The aim of this work is to investigate the predictive power of the Gamma passing rate (%GP) IMRT QA metric in order to evaluate whether the standard action levels used by most clinics are justified. Sensitivity and specificity analysis between %GP and different dose discrepancy between planned and perturbed DVH is performed. The perturbed DVH is calculated by using a dedicated software, 3DVH (Sun Nuclear Corporation), which is able to modify the dose distribution calculated by the Treatment Planning System (TPS) according to the dose discrepancies detected with pre-treatment measurements. Sensitivity was calculated to correctly identify the pre-treatment plans with high dose errors, varying the Gamma Index(GI) criteria and the preselected thresholds. Also specificity was calculated. Materials and Methods: 27 prostate cancer patients and 15 head and neck cancer patients, treated with IMRT-sliding window technique, were analyzed. Pre-treatment verifications were performed for all patients' plans by acquiring plane dose distributions of each treatment field with the diode array MapCheck (Sun Nuclear Corporation). Measured and calculated dose distributions were compared using the global and local GI method, and %GP were generated using the following acceptance criteria: 1%/1mm, 2%/2 mm, and 3%/3 mm. Planar measured dose distributions, together with patient's DICOM RT Plan, Structure and Dose files from TPS were loaded into the 3DVH software. Percentage dose differences between DVHs, obtained by TPS and by 3DVH were calculated. A value of %GP of 95% and the mean absolute DVH dose error 3% and 5% were used as thresholds to calculate sensitivity and specificity. Results: The results are reported in the Table 1 . We found an excellent sensitivity (>0.93) for global and local methods with 2%/2mm and a good sensitivity (>0.80) with 3%/3mm for local normalization. Instead we obtained a poor sensitivity (<0.4) with 3%/3mm for global normalization. Our results confirmed that in general the local normalization method is more sensitive than global. Obtained 3%/3mm specificity was always higher than 2%/2mm criterion and,in particular, for the threshold of %GP> 95%with a 2%/2mm criterion, the specificity value was very low (<0.2). So, in this case, even if the sensitivity is excellent, is not applicable in clinical routine because in our experience only 11% of plans pass this threshold. To have a higher value of specificity (>0.6) and good sensitivity (0.9) is necessary to use a threshold of %GP>90% for 2%/2mm criterion.
Conclusions:
The low sensitivity of 3%/3mm global gamma method and 95% of %GP threshold show that the most common published acceptance criteria have disputable predictive power for pre-patient IMRT QA. The %GP, although it provides the quantity of errors, does not specify the magnitude of errors. Further investigations are strongly advised concerning the clinical relevance of GI analysis. Purpose/Objective: To assess in-vivo the dose delivered to the target volume during volumetric modulated arc therapy (VMAT) in patients with anal or rectal cancer using thermoluminescent dosimeters (TLDs) whose anatomical position was evaluated using cone-beam computed tomography scans (CBCTs).
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Materials and Methods:
A new procedure was used to perform in-vivo dosimetry using TLDs placed in rectal probes in high-dose regions. Using CBCT images and image fusion, TLDs were located respect to planned treatments, and expected dose estimated. We present the results of 10 patients treated with VMAT for ano-rectal cancer. Eclipse ver.10 was used for planning and patients were treated on a 2100C/D Varian linac equipped with on-board imaging. The prescribed dose to the gross tumor volume (GTV) was 1.8 Gy and 2 Gy for patients with anal (n=8) and rectal (n=2) cancer, respectively. The delivered dose to the elective clinical target volume for rectal cancer patients was 1.8 Gy per fraction, using a simultaneous integrated boost technique. Five TLDs were fitted in a Rando phantom to evaluate TLDs readings contribution resulting from CBCT imaging. Results: TLDs reading in the Rando phantom, after irradiation with a standard pelvis CBCT protocol, resulted in 2 cGy dose contribution for all 5 TLDs, approximately 1% of the prescribed dose. These readings were neglected in the present analysis. A total of 52 measurements (43 and 9 for patients with anal and rectal cancer, respectively) were analyzed. Six TLDs were placed on the GTV located at anal verge in the perianal skin. Median planned and measured doses were 1.8 Gy (range, 1.09-2.02 Gy) and 1.81 Gy (range, 0.94-2.14 Gy), respectively. In percentage of the prescribed dose it corresponded to 100% (range, 60.6-106.7%) and 100.5% (range, 52.2-112.2%) for planned and measured values, respectively. Overall, TLD doses measurements differed by a median dose of 0.035 Gy, ranging between -0.16 and 0.21 Gy (median difference in percentage of 1.9%, range -8.9%/+11.7%) in comparison to the planned doses. Differences ≤5% or ≥5% between calculated and estimated doses were
